Repeat dosing of 60 mg AB-729 every 8 weeks resulted in mean HBsAg declines of –1.37 log10 (N=6) comparable to AB-729 dosed every 4 weeks (–1.44 log10, N=7, p
Arbutus Announces Robust HBsAg Decline Data with AB-729 Dosed at 60 mg Every 8 Weeks in Chronic Hepatitis B Subjects
On 6ix: 6ix.com/news/arbutus-announces-robust-hbsag-decline-data-with-ab-729-dosed-at-60-mg-every-8-weeks
Watch Arbutus Biopharma's latest callArbutus Biopharma (NASDAQ:ABUS) Q3 2024 Earnings Call · Replay · Nov 6, 2024Read the transcript of Arbutus Biopharma (NASDAQ:ABUS) Q3 2024 Earnings CallArbutus Biopharma Corporation on 6ix
Story so far
- Arbutus Announces Additional Robust HBsAg Decline Data with AB-729 in Chronic Hepatitis B Subjects
- Arbutus Announces Presentation of Phase 1a/1b Clinical Trial Results for AB-729 in Chronic Hepatitis B Subjects at The Liver Meeting Digital Experience™, The American Association for the Study of Liver Diseases Meeting
- Arbutus Announces AB-729 90 mg Single-Dose Week 12 Data in Chronic Hepatitis B Subjects Demonstrating Significant and Continuous Reductions in HBsAg
Earlier from Arbutus Biopharma
- Arbutus Announces Additional Robust HBsAg Decline Data with AB-729 in Chronic Hepatitis B Subjects
- Arbutus Announces Presentation of Phase 1a/1b Clinical Trial Results for AB-729 in Chronic Hepatitis B Subjects at The Liver Meeting Digital Experience™, The American Association for the Study of Liver Diseases Meeting
- Arbutus to Present at Jefferies Virtual London Healthcare Conference
- Arbutus Reports Third Quarter 2020 Financial Results and Provides Corporate Update
- Arbutus to Report Third Quarter 2020 Financial Results and Provide Corporate Update
Later from Arbutus Biopharma
- Arbutus to Participate in Virtual Fireside Chat at H.C. Wainwright BioConnect 2021 Conference
- Arbutus Announces 2021 Corporate Objectives and Provides Financial Update
- Arbutus to Report Fourth Quarter and Year End 2020 Financial Results and Provide Corporate Update
- Assembly Biosciences and Arbutus Biopharma Initiate Phase 2 Clinical Trial of Triple Combination Therapy for the Treatment of Chronic Hepatitis B Virus
- Arbutus to Participate at H.C. Wainwright Global Life Sciences Conference
Follow Arbutus Biopharma into a list and get an email when it puts out news.
Follow Arbutus Biopharma